<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496585</url>
  </required_header>
  <id_info>
    <org_study_id>14-167</org_study_id>
    <nct_id>NCT02496585</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis</brief_title>
  <official_title>Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib
      in combination with steroids, has on the lungs. Furthermore, such treatments' side effects
      will be studied together with quality of life. In addition, the investigators would like to
      determine whether they can find markers in the blood which predict worsening lung injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who are free from pulmonary exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>An acute exacerbation will be defined as (all criteria must be met):
Unexplained worsening or development of cough, dyspnea, hypoxia, or pneumonitis lasting more than 4 days
New or worsening diffuse pulmonary infiltrates on chest CT (with or without contrast) or new high resolution CT parenchymal abnormalities without significant pneumothorax or pleural effusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Metastases</condition>
  <arm_group>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <other_name>BIBF 1120</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or
             lung metastases (which are not required to be biopsy-proven) treated with definitive
             intent at MSK

          -  Prior treatment with thoracic radiotherapy completed &gt;4 weeks and ≤ 9 months prior to
             enrollment

          -  Radiographic evidence of radiation pneumonitis on a CT scan of the chest with or
             without contrast

          -  Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE
             version 4.0 criteria

          -  Age≥18 years

          -  KPS &gt; 70%

          -  Reduction of any acute toxicity from radiation treatment to grade 1

          -  Written informed consent signed prior to entry into the study

        Exclusion Criteria:

          -  Current oral steroid use &gt; 2 weeks prior to registration

          -  Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for
             this malignancy (Note: hormonal therapy is allowed)

          -  Mean esophageal radiation dose &gt;45 Gy

          -  Diagnosis of diffuse radiation pneumonitis

          -  Untreated or symptomatic brain metastases or leptomeningeal disease

          -  Liver metastases

          -  Other active malignancies requiring oncologic treatment (Note: non-melanoma skin
             cancer, superficial bladder cancer etc. are eligible)

          -  Radiographic evidence of cavitary or necrotic tumor and local invasion of major blood
             vessels

          -  Active chronic Hepatitis C and/or B infection

          -  Gastrointestinal disorders that would interfere with drug absorption

          -  AST, ALT&gt;1.5x ULN and/or Bilirubin&gt;ULN 1.5 X ULN

          -  ≥ Grade 2 proteinuria, creatinine &gt;1.5x ULN or GFR &lt;45 ml/min

          -  Other investigational therapy received within 8 weeks prior to screening visit

          -  Pregnant women or women who are breast feeding or of child bearing potential not using
             a highly effective method of birth control for at least one month prior to enrollment1

          -  Sexually active males not committing to birth control during the course of the study
             (except if their partner is not of childbearing potential)

          -  Conditions that may affect the patient's ability to participate in this trial, e.g.
             known or suspected active alcohol or drug abuse

          -  Inherited predisposition to bleeding or thrombosis, INR &gt;2, PT and PTT &gt;1.5x ULN

          -  History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic
             events within 12 months, clinically significant or tumor-related hemoptysis, active
             gastrointestinal bleeding or ulcers or major injuries or surgery

          -  ANC &lt; 1.5 K/mcL, Platelets &lt; 100 K/mcL, Hemoglobin &lt; 9.0 g/dl

          -  Concomitant treatment with any of the following drugs: azathioprine, cyclophosphamide,
             cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists,
             dabigatran, heparin), fibrinolysis and high dose anti-platelet therapy (ex. Plavix
             150mg)^2 Myocardial infarction or unstable angina within 6 or 1 month of starting
             nintedanib treatment, respectively

          -  Known inherited predisposition to thrombosis

          -  Patient with a history of a thrombotic event within 12 months of starting nintedanib
             treatment

          -  Known predisposition to bleeding

          -  Patients on fibrinolysis, full-dose therapeutic anticoagulation, or high dose
             antiplatelet therapy

          -  Patients with severe hepatic impairment

          -  History of a gastrointestinal perforation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Rimner, MD</last_name>
    <phone>212-639-6025</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Paik, MD</last_name>
    <phone>646-888-4202</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Mak, MD</last_name>
      <phone>617-632-3591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
    <contact_backup>
      <last_name>Jamie Chaft, MD</last_name>
      <phone>646-888-4545</phone>
    </contact_backup>
    <investigator>
      <last_name>Andreas Rimner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
    <contact_backup>
      <last_name>Jamie Chaft, MD</last_name>
      <phone>646-888-4545</phone>
    </contact_backup>
    <investigator>
      <last_name>Andreas Rimner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gomez, MD</last_name>
      <phone>713-563-8446</phone>
    </contact>
    <investigator>
      <last_name>Daniel Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nintedanib (BIBF 1120)</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Radiation Pneumonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

